何杰金氏淋巴瘤的非整倍体分析

应用流式细胞术和ＡｇＮｏＲｓ计数对何杰金氏淋巴瘤的非整倍体和核仁组成区资料分析。瘤细胞的ＤＮＡ指数为０．９５～１．４８，均值为１．２１±０．１２，非整倍体率为７５．０％（３０／４０），以超二倍体为主，％Ｓ和ＰＩ值分别为１８．３％和３０．６％。ＡｇＮｏＲｓ计数为２．５８～８．１４／核，均值为５．５４±０．５５。ＡｇＮｏＲｓ计数与％Ｓ有关，而与ＤＮＡ指数无关。上述分析可提供进一步对何杰金瘤细胞异质性的了解。     

ACP－BOP方案治疗非何杰金氏淋巴瘤110例临床评价

 本文报告ACP－BOP方案治疗非何杰金氏淋巴瘤（NHL）110例的临床疗效与评价。经观察，该方案取得完全缓解率为53.6%（59/110）和有效率（CR＋PR）为95.4%（105/110）的较好疗效。毒副反应不大，病人可以耐受，是治疗NHL的较好方案之一。     

Classification of peripheral t-cell lymphomas: cytogenetic findings support the updated kiel classification

The cytogenetic findings in peripheral T-cell lymphomas enabled us to distinguish not only between low and high grade peripheral T-cell lymphomas (PTL) but also between different morphologically defined subtypes. High grade lymphomas exhibited a higher frequency of aberrant clones, polyp loid chromosome numbers, a higher complexity of aberrant clones and a lower proportion of normal metaphases than low grade PTL. Moreover, deletions in 6q, trisomies of 7q and monosomy I3 or changes of 13q 14 were significantly more frequent in high grade than in low grade PTL. Translocation t(2;5)(p23;q35) was only seen in large cell anaplastic lymphoma. T-CLL/T-PLL was associated with the simultaneous presence of inversion inv(14)(ql lq32. I) and trisomy 8q, mostly due to i(8q)(q10). Trisomy 3 was a characteristic chromosome aberration of lymphoepithelioid lymphoma, AILD-type T-cell lymphoma and T-zone lymphoma. In contrast to the other low grade PTL, AILD-type T-cell lymphoma and cutaneous T-cell lymphoma showed a high frequency of unrelated clones. In summary, the cytogenetic findings paralleled the histopathologic classification according to the updated Kiel classification and support the value of the distinction of the different morphologically defined entities.     

Angiocentric B-Cell Lymphoma of the Lung in an Immunocompromised Boy

An angiocentric IgA-kappa bilateral pulmonary lymphoma developed in a 9-year-old boy treated with chemotherapy for 3 1/2 years for acute lymphoblastic leukemia. The tumor was confined to the lungs and had extensive infarction secondary to vascular involvement. This and 2 similar reported cases suggest that compromise of the host's immune system may contribute to the development of pulmonary lymphoma in children, an uncommon site and probably labeled previously as lymphomatoid granulomatosis.     

Autologous bone marrow transplantation in the treatment of children and adolescents with advanced malignant tumors

Nineteen patients with advanced malignant tumors, less than 20 years old were treated with intensive chemotherapy (vincristine 2 mg/m² i.v. and adriamycin 60 mg/m² i.v. on day ?7; cyclophosphamide 45 mg/kg i.v. on days ?6 to ?3), total body irradiation (TBI, 600 rads on day ?1) and autologous bone marrow transplantation (ABMT, day 0). Prior to this procedure induction of complete or partial remission by conventional therapy was attempted. Ten patients had intra-abdominal non-Hodgkin's lymphoma (NHL); three, yolk sac tumor; three, Ewing's sarcoma; and three, neuroblastoma. The supportive care included reverse isolation, immunoglobulin 400 mg/kg i.v. q 2 weeks, cotrimoxazole per os, and cell support as needed. No correlation between the bone marrow dose and the time of hematological reconstitution could be established. Five of seven patients with intraabdominal NHL stage III (transplanted in first remission) are surviving disease-free for 5 +, 5 +, 20 +, 23 +, and 35 + months after ABMT. None of three patients with intra-abdominal NHL stage IV is surviving (two of them were transplanted in second remission). One of three patients with yolk sac tumor is surviving disease-free for 27+ months. There are no survivors among the patients with Ewing's sarcoma and neuroblastoma. Only one of 19 patients was lost due to therapeutic complications, while 12 died due to tumor. Regarding treatment results for advanced intra-abdominal NHL, the procedure described here is comparable to the best conventional regimens. In vitro methods for tumor cell eradication in the collected bone marrow might further improve the results of ABMT.     

Follicular lymphoma in Osaka,Japan: histological features and chronological change

Follicular lymphoma (FL) is defined as a neoplastic proliferation of follicle center cells with varying follicular areas. To learn the time trend of FL in the Osaka area, an adult T-cell leukemia/lymphoma (ATL) nonendemic area of Japan, we examined the frequency of FL among all non-Hodgkin's lymphomas (NHLs) during the period 1964 to 1987 (n = 1,000) and 1999 to 2001 (n = 659).The frequency of FL with varying follicular areas increased from 1964-1987 to 1999-2001.There was a significant difference in frequency of total cases of FL (14.2% versus 18.8%) (P < .05) and FL with no to 25% follicular area (2.3% versus 5.0%) (P < .01). According to the Berard criteria, cytologic grade of FL was defined by counting the number of centroblasts (CB) in 10 neoplastic follicles as follow: < or = 5 CB per high power field (HPF), grade 1; 6-15 CB, grade 2; >15 CB, grade 3. Immunohistochemical staining with monoclonal antibodies for bcl-2 and CD10 was performed. There was an inverse correlation between follicular area and cytological grade (P < .0001) and bcl-2 expression and cytological grade (P < .01). That is, the larger the follicular area in cases with a lower cytological grade, the stronger was bcl-2 expression in a lower cytological grade. There was a significant correlation between follicular area and stage of disease (P < .05). That is, the follicular area was larger in cases in an advanced stage. This study showed the increase in frequency of FL in Osaka, Japan. Change of lifestyle in Japan may be one of the causative factors for the increase.     

Ribonucleotide reductase and thymidine phosphorylation: two potential targets of azodicarbonamide

Azodicarbonamide tested as an anti-HIV agent was reported to expulse zinc from viral zinc-cysteine factors and to inhibit calcium mobilization machinery. It has structural analogy with hydroxyurea that inhibits ribonucleotide reductase and could also act on this target. Azodicarbonamide was therefore tested for its capacity to modulate deoxyribonucleotides triphosphate pools alone or in combination with other agents in the lymphoblastic SUP-T1 cell line susceptible to HIV infection. The deoxyribonucleotides triphosphate were evaluated by an enzymatic assay using sequenase. Two hours exposure of SUP-T1 cells to 100 microM azodicarbonamide induced a 50% reduction of each deoxyribonucleotide triphosphate. Among other inhibitors of nucleotide metabolism (hydroxyurea, methotrexate and thymidine), hydroxyurea only reproduces the effect of azodicarbonamide. This suggests, but does not demonstrate directly, that azodicarbonamide inhibits ribonucleotide reductase activity. The combination of azodicarbonamide with each of these inhibitors affected particularly the dCTP pool. During this study it was also suggested that azodicarbonamide could interfere with thymidine phosphorylation. Thymidine phosphorylating activity was measured with 3H-thymidine as substrate. In acellular preparations, azodicarbonamide also non-competitively inhibits thymidine phosphorylating activity. This effect was not reproduced by hydroxyurea. Thus, in vitro azodicarbonamide decreases the intracellular pool of deoxyribonucleotide and thymidine phosphorylation.     

Risk-adjusted prognostic models for Hodgkin's disease (HD) and grade II non-Hodgkin's lymphoma (NHL II): validation on 6728 British National Lymphoma Investigation patients

Using significant factors from multivariate analyses, based on 20 putative markers from a consecutive series of 1198 Sheffield Lymphoma Group patients, risk-adjusted prognostic models had been previously derived for Hodgkin's disease (HD) (using age, albumin and lymphocyte count) and non-Hodgkin's lymphoma (NHL) grade II (based on albumin, age, erythrocyte sedimentation rate, lactate dehydrogenase and stage). Data from 6728 patients on the British National Lymphoma Investigation database were used for validation: thus the models were applied to 4411 patients with HD and 2317 patients with NHL grade II. Survival curves derived from these validation groups confirmed our risk models.